These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 22413824)

  • 21. Genetic vaccination for the active immunotherapy of cancer.
    Bronte V
    Curr Gene Ther; 2001 May; 1(1):53-100. PubMed ID: 12109138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
    Gulley JL; Arlen PM; Madan RA; Tsang KY; Pazdur MP; Skarupa L; Jones JL; Poole DJ; Higgins JP; Hodge JW; Cereda V; Vergati M; Steinberg SM; Halabi S; Jones E; Chen C; Parnes H; Wright JJ; Dahut WL; Schlom J
    Cancer Immunol Immunother; 2010 May; 59(5):663-74. PubMed ID: 19890632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic vaccines for prostate cancer.
    Cha E; Fong L
    Curr Opin Mol Ther; 2010 Feb; 12(1):77-85. PubMed ID: 20140819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilizing poxviral vectored vaccines for antibody induction-progress and prospects.
    Draper SJ; Cottingham MG; Gilbert SC
    Vaccine; 2013 Sep; 31(39):4223-30. PubMed ID: 23746455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
    Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL
    J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of poxviruses in tumor immunotherapy.
    Kaufman HL
    Surgery; 2003 Nov; 134(5):731-7. PubMed ID: 14639347
    [No Abstract]   [Full Text] [Related]  

  • 27. Methods for improving the immunogenicity and efficacy of cancer vaccines.
    Pilla L; Ferrone S; Maccalli C
    Expert Opin Biol Ther; 2018 Jul; 18(7):765-784. PubMed ID: 29874943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809).
    McNeel DG; Chen YH; Gulley JL; Dwyer AJ; Madan RA; Carducci MA; DiPaola RS
    Hum Vaccin Immunother; 2015; 11(10):2469-74. PubMed ID: 26111351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study.
    Parsons JK; Pinto PA; Pavlovich CP; Uchio E; Kim HL; Nguyen MN; Gulley JL; Jamieson C; Hsu P; Wojtowicz M; Parnes H; Schlom J; Dahut WL; Madan RA; Donahue RN; Chow HS
    Eur Urol Focus; 2018 Sep; 4(5):636-638. PubMed ID: 30197041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
    Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W
    Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Costimulatory molecules as adjuvants for immunotherapy.
    Hodge JW; Greiner JW; Tsang KY; Sabzevari H; Kudo-Saito C; Grosenbach DW; Gulley JL; Arlen PM; Marshall JL; Panicali D; Schlom J
    Front Biosci; 2006 Jan; 11():788-803. PubMed ID: 16146771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
    Cheng ML; Fong L
    Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.
    Collins JM; Redman JM; Gulley JL
    Expert Rev Vaccines; 2018 Aug; 17(8):697-705. PubMed ID: 30058393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poxviral-based prostate-specific antigen vaccine in prostate cancer.
    León L; Areses MC; Anido U; Gómez A; Carballo AM
    J Clin Oncol; 2010 Aug; 28(24):e416; author reply e417. PubMed ID: 20566998
    [No Abstract]   [Full Text] [Related]  

  • 36. Pox viral vaccine approaches.
    Arlen PM; Kaufman HL; DiPaola RS
    Semin Oncol; 2005 Dec; 32(6):549-55. PubMed ID: 16338420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of the PANVAC-VF vaccine for pancreatic cancer.
    Petrulio CA; Kaufman HL
    Expert Rev Vaccines; 2006 Feb; 5(1):9-19. PubMed ID: 16451103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promising immunotherapy for prostate cancer.
    Henegan JC; Sonpavde G
    Expert Opin Biol Ther; 2018 Feb; 18(2):109-120. PubMed ID: 29231062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer vaccines: preclinical studies and novel strategies.
    Palena C; Abrams SI; Schlom J; Hodge JW
    Adv Cancer Res; 2006; 95():115-45. PubMed ID: 16860657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design.
    Madan RA; Mohebtash M; Schlom J; Gulley JL
    Expert Opin Biol Ther; 2010 Jan; 10(1):19-28. PubMed ID: 19857185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.